Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Lemborexant in Healthy Chinese Subjects
NCT04555733Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lemborexant in Insomnia (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration for Lemborexant and Its Metabolites (M4, M9, and M10) Following Single Dose, Time to Reach the Maximum Plasma Concentration (Cmax) for Lemborexant and Its Metabolites Following Single Dose and 28 more. Started Oct 2020; status: completed.
02
Drugs
lemborexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT04555733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04555733.